Assessment of end induction minimal residual disease (MRD) in childhood B precursor acute lymphoblastic leukemia (ALL) to eliminate the need for day 14 marrow examination: A Children’s Oncology Group study.
Year: 2013
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Michael J. Borowitz, Brent L. Wood, Meenakshi Devidas, Mignon L. Loh, Elizabeth A. Raetz, Eric Larsen, Kelly W. Maloney, Andrew J Carroll, Alison M. Friedmann, Julie M Gastier-Foster, Nyla A. Heerema, Leonard A. Mattano, James B. Nachman, Naomi Joan Winick, William L. Carroll, Stephen Hunger
Institutions: Johns Hopkins Hospital, University of Washington, Children's Oncology Group, University of California, San Francisco, NYU Langone Health, Children's Hospital Colorado, Massachusetts General Hospital, Nationwide Children's Hospital, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Michigan State University, University of Chicago, Children's Medical Center, The University of Texas Southwestern Medical Center, University of Colorado Denver
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W60609056